Although evident clinical controversial data come from patients affected by melanoma and glioblastoma multiforme, studies discussed in this literature review show that PDE5 inhibition could be associated with a decreased risk of cancer development and suppression of tumor progression in several malignancies including those of the lung, prostate, breast and colorectum. Here, PDE5A is linked to cancer.